Carien L Creutzberg

List of Publications by Citations

Source: https://exaly.com/author-pdf/5749826/carien-l-creutzberg-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 137
 10,071
 50
 99

 papers
 citations
 h-index
 g-index

 149
 13,082
 5
 5.92

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
137	Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. <i>Lancet, The</i> , 2000 , 355, 1404-11	40	1369
136	Endometrial cancer. <i>Lancet, The</i> , 2016 , 387, 1094-1108	40	797
135	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 2-30	3.5	358
134	Survival after relapse in patients with endometrial cancer: results from a randomized trial. <i>Gynecologic Oncology</i> , 2003 , 89, 201-9	4.9	290
133	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. <i>Clinical Cancer Research</i> , 2016 , 22, 421	5 ⁻¹² 4 ⁹	286
132	Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 348-55	4	279
131	Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 428-34	4	268
130	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 295-309	21.7	263
129	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015 , 28, 836-44	9.8	222
128	Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1234-41	2.2	221
127	Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3547-56	2.2	216
126	Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, e631-8	4	204
125	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 12-39	3.5	203
124	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3347-3355	12.9	184
123	Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, 834-8	4	182
122	High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 35, 321-32	4	175
121	Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1692-700	2.2	174

120	Prognostic significance of POLE proofreading mutations in endometrial cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 402	9.7	169
119	The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 1246-55	4	166
118	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2018 , 143 Suppl 2, 37-50	4	166
117	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1273-1285	21.7	160
116	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancerA pooled analysis of PORTEC 1 and 2 trials. <i>European Journal of Cancer</i> , 2015 , 51, 1742-50	7.5	153
115	Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. <i>European Journal of Cancer</i> , 2011 , 47, 667-75	7.5	135
114	Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. <i>Modern Pathology</i> , 2013 , 26, 1525-35	9.8	132
113	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015 , 117, 559-81	5.3	131
112	International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology Biology Physics, 2012 , 82, 250-5	4	124
111	Sexual dysfunction and infertility as late effects of cancer treatment. <i>European Journal of Cancer, Supplement,</i> 2014 , 12, 41-53	1.6	123
110	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3388-3397	2.2	116
109	Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. <i>European Journal of Cancer</i> , 2012 , 48, 1638-48	7.5	115
108	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1114-1126	21.7	104
107	Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. <i>Cancer</i> , 2004 , 100, 764-72	6.4	99
106	Electronic portal image assisted reduction of systematic set-up errors in head and neck irradiation. <i>Radiotherapy and Oncology</i> , 2001 , 61, 299-308	5.3	93
105	Immunological profiling of molecularly classified high-risk endometrial cancers identifies -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>OncoImmunology</i> , 2017 , 6, e1264565	7.2	79
104	Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S55-60	3.5	78
103	Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. <i>European Journal of Cancer & Clinical Oncology</i> . 1988 . 24. 331-7		72

102	A quality control study of the accuracy of patient positioning in irradiation of pelvic fields. <i>International Journal of Radiation Oncology Biology Physics</i> , 1996 , 34, 697-708	4	71
101	Psychometric validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). <i>European Journal of Cancer</i> , 2011 , 47, 183-90	7.5	68
100	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1534-1542	3.5	62
99	Local control rate after the combination of re-irradiation and hyperthermia for irresectable recurrent breast cancer: Results in 248 patients. <i>Radiotherapy and Oncology</i> , 2015 , 117, 217-22	5.3	61
98	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1640-6	2.2	61
97	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 797-809	4	60
96	Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. <i>Radiotherapy and Oncology</i> , 2010 , 95, 245-9	5.3	60
95	Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 242-50	4	59
94	European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 1354-63	3.5	59
93	Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 1717-25	3.5	58
92	On-line set-up corrections during radiotherapy of patients with gynecologic tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 499-506	4	57
91	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2015, 131 Suppl 2, S96-10	044	56
90	A Transcriptionally Distinct CXCL13CD103CD8 T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 784-796	12.5	53
89	Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma. <i>Radiotherapy and Oncology</i> , 2010 , 95, 332-8	5.3	50
88	Reduction of irradiated small bowel volume and accurate patient positioning by use of a bellyboard device in pelvic radiotherapy of gynecological cancer patients. <i>Radiotherapy and Oncology</i> , 2001 , 59, 87-93	5.3	50
87	High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2014 , 133, 197	-2404	48
86	Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/Etatenin and P53 pathway activation. <i>Gynecologic Oncology</i> , 2012 , 126, 466-73	4.9	48
85	Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial. <i>Radiotherapy and Oncology</i> , 2016 , 120, 378-382	5.3	43

(2016-2016)

84	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016 , 29, 174-81	9.8	42	
83	Perceived information provision and satisfaction among lymphoma and multiple myeloma survivorsresults from a Dutch population-based study. <i>Annals of Hematology</i> , 2012 , 91, 1587-95	3	40	
82	Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, S83-9	3.5	39	
81	GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?. <i>Gynecologic Oncology</i> , 2004 , 92, 740-3	4.9	39	
8o	Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 530-9	4	38	
79	Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1499-506	3.5	36	
78	Persisting fatigue in Hodgkin lymphoma survivors: a systematic review. <i>Annals of Hematology</i> , 2013 , 92, 1023-32	3	36	
77	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 2002-2007	3.5	34	
76	Second primary cancers in survivors of cervical cancer in The Netherlands: Implications for prevention and surveillance. <i>Radiotherapy and Oncology</i> , 2014 , 111, 374-81	5.3	33	
75	Cancer of the corpus uteri. International Journal of Gynecology and Obstetrics, 2012, 119 Suppl 2, S110-7	74	32	
74	The role of radiotherapy in endometrial cancer: current evidence and trends. <i>Current Oncology Reports</i> , 2011 , 13, 472-8	6.3	32	
73	Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 52, 1067-74	4	32	
72	Adjuvant Treatment for Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. <i>Clinical Cancer Research</i> , 2018 , 24, 3197-3203	12.9	30	
71	Radiation Treatment Affects Chromosome Testing in Uveal Melanoma 2015 , 56, 5956-64		23	
7°	Qualitative accounts of patientsRdeterminants of vaginal dilator use after pelvic radiotherapy. Journal of Sexual Medicine, 2015 , 12, 764-73	1.1	22	
69	Psychosexual support for gynecological cancer survivors: professionalsRcurrent practices and need for assistance. <i>Supportive Care in Cancer</i> , 2015 , 23, 831-9	3.9	22	
68	Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature. <i>Cancer Treatment Reviews</i> , 2019 , 73, 91-103	14.4	22	
67	Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. <i>Oncotarget</i> , 2016 , 7, 39885-39893	3.3	21	

66	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017 , 23, 7232-7241	12.9	19
65	Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy. <i>Acta Oncolgica</i> , 2013 , 52, 745-52	3.2	19
64	Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. <i>Gynecologic Oncology</i> , 2020 , 159, 649-656	4.9	19
63	International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. <i>Quality of Life Research</i> , 2018 , 27, 333-345	3.7	19
62	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer <i>Journal of Clinical Oncology</i> , 2017 , 35, 5502-5502	2.2	18
61	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021 , 478, 153-19	$ar{\phi}^{.1}$	18
60	Ruthenium plaque radiation therapy for iris and iridociliary melanomas. <i>Acta Ophthalmologica</i> , 2012 , 90, 291-6	3.7	17
59	NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 413-424	4	17
58	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021 , 154, 327-353	5.3	17
57	Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf& clothing. <i>Histopathology</i> , 2018 , 72, 248-258	7.3	17
56	Lymphadenectomy in apparent early-stage endometrial carcinoma: do numbers count?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3653-5	2.2	16
55	ESGO Survey on Current Practice in the Management of Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1226-1231	3.5	16
54	Phase 1-3 of the cross-cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ-22. <i>Cancer Medicine</i> , 2018 , 7, 635-645	4.8	15
53	PatientsRand cliniciansRpreferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> , 2016 , 115, 1179-1185	8.7	15
52	Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. <i>European Journal of Cancer</i> , 2016 , 68, 106-113	7.5	15
51	Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 594-604	3.5	15
50	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. <i>Cancer Immunology Research</i> , 2020 , 8, 1508-1519	12.5	14
49	Cancer of the corpus uteri: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 155 Suppl 1, 45-60	4	14

(2017-2015)

48	Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2015 , 139, 458-64	4.9	13	
47	Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors. <i>Current Oncology Reports</i> , 2019 , 21, 83	6.3	13	
46	Chest wall irradiation with MLC-shaped photon and electron fields. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 1205-17	4	13	
45	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. <i>Oncotarget</i> , 2017 , 8, 25542-25551	3.3	12	
44	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3623-3632	2.2	12	
43	ENdometrial cancer SURvivorsRfollow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial. <i>Trials</i> , 2018 , 19, 227	2.8	11	
42	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1212-1220	9.7	11	
41	Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?. <i>Radiotherapy and Oncology</i> , 2016 , 120, 397-403	5.3	10	
40	Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2490-2500	2.2	10	
39	Long-term risk of secondary skin cancers after radiation therapy for Hodgkinß lymphoma. <i>Radiotherapy and Oncology</i> , 2013 , 109, 140-5	5.3	10	
38	Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 257-265	3.5	9	
37	Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. <i>Practical Radiation Oncology</i> , 2015 , 5, e557-65	2.8	9	
36	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , 2020 , 13,	6.6	9	
35	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 152, 102973	7	9	
34	Adjuvant chemotherapy for endometrial cancer: unproven. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 1105-8	3.5	8	
33	Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 51-60	3.5	8	
32	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 975-986	4	7	
31	A Controlled Study on Vaginal Blood Flow During Sexual Arousal Among Early-Stage Cervical Cancer Survivors Treated With Conventional Radical or Nerve-Sparing Surgery With or Without Radiotherapy International Journal of Gynecological Cancer 2017, 27, 1051-1057	3.5	6	

30	Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed. <i>Lancet Oncology, The</i> , 2016 , 17, 132-134	21.7	6
29	Rectal bleeding after radiation therapy for endometrial cancer. <i>Radiotherapy and Oncology</i> , 2015 , 115, 240-5	5.3	6
28	Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016 , 60, 554-9	1.7	5
27	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019 , 8,	7.9	4
26	Ruthenium-106 brachytherapy for iris and iridociliary melanomas. <i>British Journal of Ophthalmology</i> , 2018 , 102, 1154-1159	5.5	4
25	Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 164-71	4	3
24	Point: Vaginal brachytherapy should be a standard adjuvant treatment for intermediate-risk endometrial cancer. <i>Brachytherapy</i> , 2011 , 10, 1-3	2.4	3
23	Adjuvant chemotherapy for endometrial cancer: unproven. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, S60-3	3.5	3
22	Management of conjunctival melanoma with local excision and adjuvant brachytherapy. <i>Eye</i> , 2021 , 35, 490-498	4.4	3
21	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients <i>Nature Communications</i> , 2022 , 13, 1373	17.4	3
21		17.4	3
	Communications, 2022, 13, 1373 Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial Journal		
20	Communications, 2022, 13, 1373 Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial Journal of Clinical Oncology, 2015, 33, 5501-5501 STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent	2.2	2
20	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5501-5501 STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5615-TPS5615 Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). <i>European Journal of Cancer</i> ,	2.2	2
20 19 18	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5501-5501 STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5615-TPS5615 Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). <i>European Journal of Cancer</i> , 2021 , 154, 235-245 Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy.	2.2 2.2 7.5	2 2 2
20 19 18	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5501-5501 STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5615-TPS5615 Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). <i>European Journal of Cancer</i> , 2021 , 154, 235-245 Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to	2.2 2.2 7.5	2 2 2
20 19 18 17	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial <i>Journal of Clinical Oncology</i> , 2015 , 33, 5501-5501 STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS5615-TPS5615 Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). <i>European Journal of Cancer</i> , 2021 , 154, 235-245 Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System. <i>Cancers</i> , 2021 , 13,	2.2 2.2 7.5 4 6.6	2 2 2 1 1

LIST OF PUBLICATIONS

12	Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6 1	-
11	Differences in health care professionalsRand cancer patientsRviews on sexual health issues. <i>Psycho-Oncology</i> , 2018 , 27, 2299-2302	3.9 1	
10	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. <i>Gynecologic Oncology</i> , 2021 , 163, 117-124	4.9 1	<u>.</u>
9	A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial. <i>BMC Cancer</i> , 2021 , 21, 1295	4.8 1	
8	Automated causal inference in application to randomized controlled clinical trials. <i>Nature Machine Intelligence</i> ,	22.5 1	-
7	Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 947	3.5 C)
6	Reply to M. Wissing et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1862	2.2	
5	InvestigatorsResponse. <i>Lancet Oncology, The</i> , 2018 , 19, 602	21.7	
4	Uterus467-478		
3	Uterus467-478		
2	Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors <i>Journal of Clinical Oncology</i> , 2013 , 31, 8568-8568	2.2	
1	Vaginal brachytherapy management of stage I and II endometrial cancer <i>International Journal of Gynecological Cancer</i> , 2022 , 32, 304-310	3.5	